Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split effective at 12:01 a.m. ET on January 29, 2026.

Rhea-AI Summary

Bluejay Diagnostics (NASDAQ: BJDX) announced a 1-for-4 reverse stock split effective at 12:01 a.m. ET on January 29, 2026. At the effective time every four issued and outstanding shares will be combined into one share, reducing outstanding common stock from approximately 2,834,133 shares to approximately 708,533. The company’s trading symbol BJDX remains unchanged and a new CUSIP 095633608 will be used post-split. Prefunded warrants will be adjusted from 1,055,000 to 263,750. No fractional shares will be issued; holders will receive a cash payment in lieu of fractional shares. Transfer agent Continental Stock Transfer & Trust Company will act as exchange agent and certificate holders will receive instructions. Equity awards and warrants will be proportionally adjusted.

The company noted it does not yet have FDA clearance for its Symphony System; its IL-6 sepsis test is designed for ~20-minute sample-to-result performance.

Positive

• Outstanding common shares consolidated from ~2,834,133 to ~708,533
• Prefunded warrants adjusted from 1,055,000 to 263,750
• New post-split CUSIP: 095633608
• Transfer agent Continental appointed as exchange agent for the split

Negative

• No fractional shares issued; holders receive cash in lieu which may alter small holdings
• The company does not yet have FDA clearance for the Symphony System, delaying U.S. commercialization

Argus Jan 27 session

-3.87% close to close Open Argus

Details

News Market Reaction – BJDX

On Jan 27, the day this news came out, BJDX closed 3.87% below the previous close.

Data tracked by StockTitan Argus for the Jan 27 session.

Key Figures

Reverse split ratio: 1-for-4 Outstanding shares pre-split: 2,834,133 shares Outstanding shares post-split: 708,533 shares +5 more

Reverse split ratio

1-for-4

Every 4 pre-split shares become 1 post-split share

Outstanding shares pre-split

2,834,133 shares

Common stock before January 29, 2026 reverse split

Outstanding shares post-split

708,533 shares

Common stock after 1-for-4 reverse split

Prefunded warrants pre-split

1,055,000 shares

Common shares issuable on exercise before split

Prefunded warrants post-split

263,750 shares

Common shares issuable on exercise after split

Par value per share

$0.0001

Par value unchanged by reverse split

Effective time

12:01 a.m. ET, Jan 29, 2026

Reverse split effectiveness and start of post-split trading

Symphony IL-6 test time

20 minutes

Sample-to-result time for IL-6 sepsis test candidate

Previous Stock split Reports

2 past events · Latest: Nov 13

Same Type 2 events

1. Nov 13

   Reverse stock split

   24h Move

   -28.9%

   Announced 1-for-50 reverse split, sharply reducing outstanding common shares.

2. Jun 17

   Reverse stock split

   24h Move

   -20.4%

   Announced 1-for-8 reverse split to cut shares outstanding and adjust share price.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

reverse stock split, cusip, prefunded warrants, equity awards, +4 more

8 terms

reverse stock split financial

"approved a reverse stock split of its shares of common stock at a ratio of 1-for-4"

A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.

cusip financial

"common stock will also commence trading with a new CUSIP number, 095633608"

A CUSIP is a nine-character alphanumeric code that uniquely identifies a U.S. or Canadian financial security—such as a stock, bond, or fund share—like a Social Security number for an investment. It matters to investors because brokers, exchanges and record-keepers use the CUSIP to match trades, track ownership, settle transactions and pull accurate records, reducing errors and ensuring money and securities go to the right place.

View in glossary

prefunded warrants financial

"reduce the number of shares of the Company’s common stock issuable upon the exercise of prefunded warrants from 1,055,000"

Prefunded warrants are a security that gives the holder the right to convert the warrant into a share after paying a very small remaining amount because almost the full purchase price was paid upfront. They matter to investors because exercising them increases the company’s outstanding shares (dilution) and can provide immediate cash to the issuer while allowing holders to bypass ownership limits or simplify timing, similar to buying a nearly-complete gift card that only needs a tiny top-up to use.

equity awards financial

"The shares underlying the Company’s outstanding equity awards and warrants will also be adjusted"

Equity awards are payments to employees or directors made in the form of company stock or rights to buy stock later, serving as a way to share ownership rather than cash. For investors, they matter because they align staff incentives with company performance, can increase the number of shares outstanding over time (which can reduce each share’s claim on profits), and create compensation costs that affect reported earnings.

transfer agent financial

"The Company has retained its transfer agent, Continental Stock Transfer & Trust Company"

A transfer agent is a financial service that keeps the official record of who owns a company's shares, handles the buying and selling of those shares on paper or electronically, and issues or cancels stock certificates. Think of it as the company’s records keeper and mailroom combined—investors rely on it to make sure dividends, shareholder mailings, ownership changes, and proxy voting are processed accurately and securely, which protects ownership rights and helps prevent errors or fraud.

near-patient testing technical

"a cost-effective, rapid, near-patient testing system for sepsis triage"

Near-patient testing means medical tests performed close to where a patient is being seen — for example in a clinic, pharmacy, ambulance, or at home — instead of being sent to a distant laboratory. For investors, it matters because these faster, simpler tests can speed diagnosis and treatment, broaden access, lower ongoing costs, and create new sales and recurring-revenue opportunities much like a compact kitchen appliance that brings restaurant capabilities into the home.

il-6 medical

"Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed"

Interleukin-6 (IL-6) is a small signaling protein the body releases as an alarm during infection, injury, or chronic inflammation; think of it as a smoke detector that calls immune cells to action. It matters to investors because IL-6 levels can serve as a biomarker for disease severity and a target for therapies—drugs that block or modulate IL-6 can change treatment outcomes, regulatory decisions, and commercial prospects in healthcare markets.

u.s. food and drug administration regulatory

"we will need to receive regulatory authorization from the U.S. Food and Drug Administration"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-4 (the “Reverse Stock Split”). The Reverse Stock Split will become effective at 12:01 a.m. Eastern Time on January 29, 2026, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on January 29, 2026 under the Company’s existing trading symbol, “BJDX.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 095633608.

At the effective time of the reverse stock split, every four (4) issued and outstanding shares of Bluejay common stock will be combined into one (1) share of common stock, with no change to the par value of $0.0001 per share. This will reduce the Company’s outstanding common stock from approximately 2,834,133 shares to approximately 708,533 shares (and reduce the number of shares of the Company’s common stock issuable upon the exercise of prefunded warrants from 1,055,000 to 263,750). No fractional shares of common stock will be issued as a result of the reverse stock split and instead holders of Bluejay common stock will receive a cash payment in lieu of fractional shares to which they would otherwise be entitled. The shares underlying the Company’s outstanding equity awards and warrants will also be adjusted accordingly. The reverse stock split affects all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s common stock, except for adjustments that may result from the treatment of fractional shares.

The Company has retained its transfer agent, Continental Stock Transfer & Trust Company (“Continental”), to act as its exchange agent for the reverse stock split. Stockholders with shares held in certificate form will receive from Continental instructions regarding the exchange of their certificates. Stockholders that hold shares in book-entry form or hold their shares in brokerage accounts are not required to take any action and will see the impact of the reverse stock split reflected in their accounts, subject to brokers’ particular processes. Beneficial holders of Bluejay common stock are encouraged to contact their bank, broker, custodian or other nominee with questions regarding procedures for processing the reverse stock split.

About Bluejay Diagnostics:

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes using its Symphony System, a cost-effective, rapid, near-patient testing system for sepsis triage and monitoring of disease progression. Bluejay does not yet have regulatory clearance for the Symphony System, and we will need to receive regulatory authorization from the U.S. Food and Drug Administration before Symphony can be marketed as a diagnostic product in the United States. Bluejay’s first product candidate, an IL-6 Test for sepsis, is designed to provide accurate, reliable results in approximately 20 minutes from ’sample-to-result’ to help medical professionals make earlier and better triage/treatment decisions. More information is available at www.bluejaydx.com.

Forward-Looking Statements:

This press release contains statements that the Company believes are “forward-looking statements” within the meaning of the Private Litigation Reform Act. Forward-looking statements may be identified by words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “suggest,” “will,” and similar expressions. The Company has based these forward-looking statements on its current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements the Company makes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including market and other conditions and those discussed under item 1A. “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as filed with the Securities and Exchange Commission (the “SEC”) on March 31, 2025, and in Part II, Item 1A, “Risk Factors” in the Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025 and September 30, 2025, filed with the SEC on May 13, 2025, August 7, 2025 and November 7, 2025, respectively. You should not place undue reliance on these forward-looking statements, as they are subject to risks and uncertainties, and actual results and performance in future periods may not occur or may be materially different from any future results or performance suggested by the forward-looking statements in this release. This press release speaks as of the date indicated above. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. The Company expressly disclaims any obligation to update or revise any forward-looking statements found herein to reflect any future changes in the Company’s expectations of results or any future change in events, except as required by law.

Investor Contact:
Neil Dey
Bluejay Diagnostics, Inc.
neil.dey@bluejaydx.com
978-631-0310

Website: www.bluejaydx.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the effective date of Bluejay Diagnostics' 1-for-4 reverse stock split (BJDX)?

The reverse stock split becomes effective at 12:01 a.m. ET on January 29, 2026, and BJDX will trade post-split that day.

How many shares will Bluejay (BJDX) have outstanding after the 1-for-4 reverse split?

Outstanding common stock will be reduced from approximately 2,834,133 shares to approximately 708,533 shares.

Will Bluejay (BJDX) change its ticker or CUSIP after the reverse split?

The trading symbol remains BJDX; the company will commence trading with a new CUSIP, 095633608, on January 29, 2026.

What happens to fractional shares from Bluejay's 1-for-4 reverse split?

No fractional shares will be issued; holders entitled to fractional shares will receive a cash payment in lieu of the fractional share.

Do Bluejay stockholders need to take action for the BJDX reverse split?

Holders in brokerage accounts or book-entry form need not take action; stockholders holding physical certificates will receive exchange instructions from Continental.

How are Bluejay's warrants and equity awards affected by the 1-for-4 split?

Outstanding equity awards and warrants will be adjusted proportionally, including prefunded warrants changing from 1,055,000 to 263,750.